Publications:
1. Cromer MK, Majeti KR, Rettig GR, Murugan K, Kurgan GL, Hampton JP, Vakulskas CA, Behlke MA, Porteus MH. Comparative analysis of CRISPR off-target activity discovery tools following ex vivo editing of CD34+ hematopoietic stem and progenitor cells. bioRxiv (under review at Molecular Therapy), (2022).
2. Wienert B, Cromer MK. CRISPR nuclease off-target activity detection and mitigation strategies. Frontiers in Genome Editing (accepted-in-principle), (2022).
3. Cromer MK,* Barsan VV,* Jaeger E, Wang M, Hampton JP, Chen F, Kennedy D, Xiao J, Khrebtukova I, Granat A, Truong T, Porteus MH. Ultra-deep sequencing validates safety of CRISPR/Cas9 genome editing in human hematopoietic stem and progenitor cells. Nature Communications, 13(1):4724 (2022).
4. Cromer MK,* Camarena J,* Martin RM, Lesch BJ, Vakulskas CA, Bode NM, Kurgan G, Collingwood MA, Rettig GR, Behlke MA, Lemgart VT, Zhang Y, Goyal A, Zhao F, Srifa W, Ponce E, Bak RO, Uchida N, Majeti R, Tisdale JF, Dever DP, Porteus MH. Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem & progenitor cells. Nature Medicine 27:677–87 (2021).
5. Lattanzi A, Camarena J, Lahiri P, Segal H, Srifa W, Vakulskas CA, Frock RL, Kenrick J, Lee C, Talbott N, Skowronski J, Cromer MK, Charlesworth CT, Bak RO, Bao G, DiGiusto D, Tisdale J, Wright JF, Bathia N, Roncarolo MG, Dever DP, Porteus MH. Development of β-globin gene correction in human hematopoietic stem cells as a potential durable treatment for sickle cell disease. Science Translational Medicine 13(598): eabf2444 (2021).
6. Martin RM,* Fowler JL,* Cromer MK, Lesch BJ, Ponce E, Uchida N, Nishimura T, Porteus MH, Loh KM. Improving the safety of human pluripotent stem cell therapies using genome-edited orthogonal safeguard. Nature Communications 11:2713 (2020).
7. de Alencastro G, Puzzo F, Pavel-Dinu M, Zhang F, Pillay S, Majzoub K, Tiffany M, Jang H, Sheikali A, Cromer MK, Meetei R, Carette J, Porteus MH, Pekrun K, Kay MA. Improved genome editing through inhibition of FANCM & members of the BTR dissolvase complex. Molecular Therapy 29(3):1016-27 (2020).
8. Martin RM,* Ikeda K,* Cromer MK,* Uchida N, Nishimura T, Romano R, Tong AJ, Lemgart V, Camarena J, Pavel-Dinu M, Sindhu C, Weibking V, Vaidyanathan S, Dever DP, Bak RO, Lausten A, Lesch BJ, Jakobsen MR, Sebastiano V, Nakauchi H, Porteus MH. Selection-free, high frequency genome editing by homologous recombination of human pluripotent stem cells using Cas9/AAV6. Cell Stem Cell 24(5):821-8 (2019).
9. Charlesworth CT, Deshpande PS, Dever DP, Camarena J, Lemgart V, Cromer MK, Vakulskas CA, Collingwood MA, Zhang L, Bode NM, Behlke MA, Dejene B, Cieniewicz B, Romano R, Lesch B, Gomez-Ospina N, Mantri S, Pavel-Dinu M, Weinberg KI, Porteus MH. Identification of pre-existing adaptive immunity to Cas9 proteins in humans. Nature Medicine 25(2):249-54 (2019).
10. Cromer MK, Vaidyanathan S, Ryan DE, Curry B, Lucas AB, Camarena J, Kaushik M, Hay SR, Steinfeld I, Martin RM, Bak RO, Dever DP, Hendel A, Bruhn L, Porteus MH. Global transcriptional response to CRISPR/Cas9-AAV6 based genome editing in CD34+ hematopoietic stem & progenitor cells. Molecular Therapy 26(8):30261-2 (2018).
11. Charlesworth CT, Camarena J, Cromer MK, Vaidyanathan S, Bak RO, Carte J, Potter J, Dever DP, Porteus MH. Priming hematopoietic stem & progenitor cells for CRISPR/Cas9-mediated homologous recombination & ex vivo expansion of targeted cells. Molecular Therapy Nucleic Acids 12:89-104 (2018).
12. Cromer MK, Choi M, Nelson-Williams C, Fonseca AL, Kunstman JW, Korah RJ, Overton J, Mane S, Kenney B, Malchoff CD, Stalberg P, Akerström G, Westin G, Hellman P, Carling T, Björklund P, Lifton RP. Neomorphic effects of recurrent somatic mutations in YY1 in insulin-producing adenomas. PNAS 112(13):4062-7 (2015).
13. Cromer MK, Starker LF, Choi M, Udelsman R, Nelson-Williams C, Lifton RP, Carling T. Identification of somatic mutations in parathyroid tumors using whole-exome sequencing. Journal of Clinical Endocrinology & Metabolism 97, E1774 (2012).